Skip to main content

Table 3 Characteristics of patients in the validation and initial cohorts

From: Identification of definitive serum biomarkers associated with disease activity in primary Sjögren’s syndrome

Characteristic Validation cohort (n = 58) Initial cohort (n = 30)
Demographic   
 Female, n (%) 57 (98) 29 (97)
 Age, mean (SD), years* 60.3 (13.3) 61.1 (10.8)
 Disease duration, mean (SD), years* 3.5 (5.8) 4.7 (6.6)
Clinical manifestation, n (%)   
 Ocular symptoms 39 (67) 18 (60)
 Oral symptoms 53 (91) 21 (70)
 Objectively assessed dryness 48 (83) 24 (80)
 Anti-SSA positivity 43 (74) 24 (80)
 Anti-SSB positivity 24 (41) 14 (48)
 Lymphocytic sialadenitis with focus score ≥1 10 (17) 12 (40)
ESSDAI, mean score (SD)* 2.6 (4.9) 2.6 (4.2)
Treatment   
 Corticosteroid 1 (1.7) 1 (3)
 Immunosuppressant 0 (0) 0 (0)
  1. *Data are presented as mean ± SD or number (%). Anti-SSA anti-Sjögren’s syndrome antigen A antibodies, Anti-SSB anti-Sjögren’s syndrome antigen B antibodies, ESSDAI European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index